These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 7586937)
1. A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Berlin I; Saïd S; Spreux-Varoquaux O; Launay JM; Olivares R; Millet V; Lecrubier Y; Puech AJ Clin Pharmacol Ther; 1995 Oct; 58(4):444-52. PubMed ID: 7586937 [TBL] [Abstract][Full Text] [Related]
2. A double-blind, placebo-controlled, randomized clinical trial of oral selegiline hydrochloride for smoking cessation in nicotine-dependent cigarette smokers. Weinberger AH; Reutenauer EL; Jatlow PI; O'Malley SS; Potenza MN; George TP Drug Alcohol Depend; 2010 Mar; 107(2-3):188-95. PubMed ID: 19939587 [TBL] [Abstract][Full Text] [Related]
3. A selective reversible monoamine oxidase B inhibitor in smoking cessation: effects on its own and in association with transdermal nicotine patch. Berlin I; Hunneyball IM; Greiling D; Jones SP; Fuder H; Stahl HD Psychopharmacology (Berl); 2012 Sep; 223(1):89-98. PubMed ID: 22451094 [TBL] [Abstract][Full Text] [Related]
4. Lazabemide, a selective, reversible monoamine oxidase B inhibitor, as an aid to smoking cessation. Berlin I; Aubin HJ; Pedarriosse AM; Rames A; Lancrenon S; Lagrue G; Addiction; 2002 Oct; 97(10):1347-54. PubMed ID: 12359039 [TBL] [Abstract][Full Text] [Related]
5. Initial monoamine oxidase-A inhibition by moclobemide does not predict the therapeutic response in patients with major depression. A double blind, randomized study. Radat F; Berlin I; Spreux-Varoquaux O; Elatki S; Ferreri M; Puech AJ Psychopharmacology (Berl); 1996 Oct; 127(4):370-6. PubMed ID: 8923574 [TBL] [Abstract][Full Text] [Related]
6. Effects of past history of major depression on smoking characteristics, monoamine oxidase-A and -B activities and withdrawal symptoms in dependent smokers. Berlin I; Spreux-Varoquaux O; Saïd S; Launay JM Drug Alcohol Depend; 1997 Apr; 45(1-2):31-7. PubMed ID: 9179504 [TBL] [Abstract][Full Text] [Related]
7. Treatment of winter depression in Norway. II. A comparison of the selective monoamine oxidase A inhibitor moclobemide and placebo. Lingjaerde O; Reichborn-Kjennerud T; Haggag A; Gärtner I; Narud K; Berg EM Acta Psychiatr Scand; 1993 Nov; 88(5):372-80. PubMed ID: 8296582 [TBL] [Abstract][Full Text] [Related]
8. Monoamine oxidase A and B activities in heavy smokers. Berlin I; Said S; Spreux-Varoquaux O; Olivares R; Launay JM; Puech AJ Biol Psychiatry; 1995 Dec; 38(11):756-61. PubMed ID: 8580230 [TBL] [Abstract][Full Text] [Related]
9. Double-blind randomized controlled study of the efficacy and tolerability of two reversible monoamine oxidase A inhibitors, pirlindole and moclobemide, in the treatment of depression. Tanghe A; Geerts S; Van Dorpe J; Brichard B; Bruhwyler J; Géczy J Acta Psychiatr Scand; 1997 Aug; 96(2):134-41. PubMed ID: 9272198 [TBL] [Abstract][Full Text] [Related]
10. Moclobemide: a reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group. J Affect Disord; 1993 Jun; 28(2):105-16. PubMed ID: 8354766 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of reversible inhibitors of monoamine oxidase-A in various forms of depression. Lecrubier Y; Guelfi JD Acta Psychiatr Scand Suppl; 1990; 360():18-23. PubMed ID: 2248063 [TBL] [Abstract][Full Text] [Related]
12. Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers. Illi A; Sundberg S; Ojala-Karlsson P; Scheinin M; Gordin A Clin Pharmacol Ther; 1996 Apr; 59(4):450-7. PubMed ID: 8612391 [TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of moclobemide and selegiline on tyramine-evoked mydriasis in man. Bitsios P; Langley RW; Tavernor S; Pyykkö K; Scheinin M; Szabadi E; Bradshaw CM Br J Clin Pharmacol; 1998 Jun; 45(6):551-8. PubMed ID: 9663810 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers. Koulu M; Scheinin M; Kaarttinen A; Kallio J; Pyykkö K; Vuorinen J; Zimmer RH Br J Clin Pharmacol; 1989 Feb; 27(2):243-55. PubMed ID: 2469451 [TBL] [Abstract][Full Text] [Related]
15. The therapeutic potential of moclobemide, a reversible selective monoamine oxidase A inhibitor in Parkinson's disease. Sieradzan K; Channon S; Ramponi C; Stern GM; Lees AJ; Youdim MB J Clin Psychopharmacol; 1995 Aug; 15(4 Suppl 2):51S-59S. PubMed ID: 7593732 [TBL] [Abstract][Full Text] [Related]
16. A double-blind placebo-controlled comparison of moclobemide and amitriptyline in the treatment of depression. Bakish D; Wiens A; Ellis J; Alda M; Lapierre Y Can J Psychiatry; 1992 Sep; 37 Suppl 1():12-7. PubMed ID: 1394026 [TBL] [Abstract][Full Text] [Related]
17. A placebo-controlled study of the antidepressant activity of moclobemide, a new MAO-A inhibitor. Casacchia M; Carolei A; Barba C; Frontoni M; Rossi A; Meco G; Zylberman MR Pharmacopsychiatry; 1984 Jul; 17(4):122-5. PubMed ID: 6382361 [TBL] [Abstract][Full Text] [Related]
20. Moclobemide and imipramine in chronic depression (dysthymia): an international double-blind, placebo-controlled trial. International Collaborative Study Group. Versiani M; Amrein R; Stabl M Int Clin Psychopharmacol; 1997 Jul; 12(4):183-93. PubMed ID: 9347378 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]